Compare Stocks: ERYP, CYH, FHTX, and LXEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYH Community Health Systems	$3.01 -0.2%	$3.14	$2.40 ▼ $4.43	$424.44M	1.84	1.38 million shs	685,028 shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
FHTX Foghorn Therapeutics	$6.87 -2.8%	$5.35	$3.27 ▼ $7.61	$419.85M	2.89	298,127 shs	402,913 shs
LXEO Lexeo Therapeutics	$4.92 +0.8%	$4.73	$3.99 ▼ $10.99	$400.39M	1.46	919,866 shs	518,496 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYH Community Health Systems	-0.50%	+1.86%	+11.50%	+5.44%	+9.07%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
FHTX Foghorn Therapeutics	-2.83%	+1.93%	+41.65%	+57.21%	+23.56%
LXEO Lexeo Therapeutics	+0.82%	-1.20%	+5.58%	-4.28%	+0.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYH Community Health Systems	$3.01 -0.2%	$3.14	$2.40 ▼ $4.43	$424.44M	1.84	1.38 million shs	685,028 shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
FHTX Foghorn Therapeutics	$6.87 -2.8%	$5.35	$3.27 ▼ $7.61	$419.85M	2.89	298,127 shs	402,913 shs
LXEO Lexeo Therapeutics	$4.92 +0.8%	$4.73	$3.99 ▼ $10.99	$400.39M	1.46	919,866 shs	518,496 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYH Community Health Systems	-0.50%	+1.86%	+11.50%	+5.44%	+9.07%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
FHTX Foghorn Therapeutics	-2.83%	+1.93%	+41.65%	+57.21%	+23.56%
LXEO Lexeo Therapeutics	+0.82%	-1.20%	+5.58%	-4.28%	+0.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYH Community Health Systems	1.71	Reduce	$2.95	-1.83% Downside
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
FHTX Foghorn Therapeutics	2.88	Moderate Buy	$11.43	66.35% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	281.10% Upside

Current Analyst Ratings Breakdown

Latest ERYP, CYH, FHTX, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/27/2026	CYH Community Health Systems	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.75 ➝ $3.25
7/27/2026	CYH Community Health Systems	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$5.00 ➝ $4.00
7/24/2026	CYH Community Health Systems	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$3.20 ➝ $3.00
7/23/2026	CYH Community Health Systems	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$3.00 ➝ $2.50
7/17/2026	FHTX Foghorn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CYH Community Health Systems	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$3.00 ➝ $3.75
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	CYH Community Health Systems	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$3.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYH Community Health Systems	$12.49B	0.03	$4.23 per share	0.71	($8.37) per share	-0.36
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
FHTX Foghorn Therapeutics	$30.91M	13.20	N/A	N/A	($1.92) per share	-3.58
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYH Community Health Systems	$509M	$1.85	1.62	N/A	N/A	2.10%	-6.66%	0.62%	10/22/2026 (Estimated)
ERYP ERYTECH Pharma	-$240K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A

Latest ERYP, CYH, FHTX, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million
7/22/2026	Q2 2026	CYH Community Health Systems	-$0.1036	-$0.19	-$0.0864	$0.51	$2.89 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYH Community Health Systems	N/A	N/A	N/A	N/A	N/A
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYH Community Health Systems	N/A	1.53	1.39
ERYP ERYTECH Pharma	0.32	3.65	3.65
FHTX Foghorn Therapeutics	N/A	3.36	3.36
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYH Community Health Systems	84.99%
ERYP ERYTECH Pharma	1.09%
FHTX Foghorn Therapeutics	61.55%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
CYH Community Health Systems	11.10%
ERYP ERYTECH Pharma	1.94%
FHTX Foghorn Therapeutics	9.02%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYH Community Health Systems	57,000	141.01 million	125.36 million	Optionable
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
FHTX Foghorn Therapeutics	120	59.38 million	54.03 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable

ERYP, CYH, FHTX, and LXEO Headlines

Recent News About These Companies

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 3,345 Shares of Stock

August 20, 2026 | insidertrades.com

Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares

August 19, 2026 | marketbeat.com

Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

August 19, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

August 13, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

August 12, 2026 | marketbeat.com

Lexeo Therapeutics advances gene therapy and gains RMAT status

August 12, 2026 | tipranks.com

Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020

August 12, 2026 | quiverquant.comQ

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

August 12, 2026 | globenewswire.com

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

August 12, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

August 10, 2026 | marketbeat.com

Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

August 5, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

August 3, 2026 | marketbeat.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%

July 31, 2026 | aaii.comA

Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital

July 31, 2026 | marketbeat.com

Orbimed Advisors LLC Purchases 1,477,450 Shares of Lexeo Therapeutics, Inc. $LXEO

July 27, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP

July 27, 2026 | marketbeat.com

Lexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor Focus

July 22, 2026 | tipranks.com

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

July 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, CYH, FHTX, and LXEO Company Descriptions

Community Health Systems NYSE:CYH

$3.00 -0.01 (-0.17%)

Closing price 08/24/2026 03:59 PM Eastern

Extended Trading

$3.00 0.00 (0.00%)

As of 08/24/2026 04:20 PM Eastern

Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee.

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Foghorn Therapeutics NASDAQ:FHTX

$6.87 -0.20 (-2.83%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$6.75 -0.12 (-1.73%)

As of 04:34 AM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.92 +0.04 (+0.82%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$4.93 +0.01 (+0.16%)

As of 05:24 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ERYP, CYH, FHTX, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ERYP, CYH, FHTX, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ERYP, CYH, FHTX, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, CYH, FHTX, and LXEO Company Descriptions

Community Health Systems NYSE:CYH

ERYTECH Pharma NASDAQ:ERYP

Foghorn Therapeutics NASDAQ:FHTX

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ERYP, CYH, FHTX, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ERYP, CYH, FHTX, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ERYP, CYH, FHTX, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, CYH, FHTX, and LXEO Company Descriptions

Community Health Systems NYSE:CYH

ERYTECH Pharma NASDAQ:ERYP

Foghorn Therapeutics NASDAQ:FHTX

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools